MedTrace Logo

Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin

NCT01847677 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2020-04-01

No results posted yet for this study

Summary

Recently results have shown that Bevacizumab is active both in monotherapy and in combination therapy in patients with ovarian cancer. One of our objectives is to evaluate whether the addition of neoadjuvant bevacizumab improves the response and whether this affects the evolution of patients.

Conditions

  • Cancer, Ovarian

Interventions

DRUG

Bevacizumab

DRUG

Paclitaxel

DRUG

Carboplatin

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Grupo Español de Investigación en Cáncer de Ovario

    lead OTHER

Principal Investigators

  • Yolanda García, MD · C.S Parc Taulí

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-06
Primary Completion
2015-06-04
Completion
2019-05-17

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01847677 on ClinicalTrials.gov